Botticelli et al. found that higher IDO activity in circulating blood revealed the resistance to PD-1 inhibitor immunotherapy in lung cancer which suggested the potential benefit of PD-1 inhibitor immunotherapy combined with IDO inhibitors in patients with higher IDO [37]. This evidence concerns the gene PDCD1 and lung carcinoma.